NCT03809013View on ClinicalTrials.gov

A Open-label, Single-arm, Multicenter, Phase II Study of RC48-ADC to Evaluate the Efficacy and Safety of Subjects With HER2 Overexpressing Locally Advanced or Metastatic Urothelial Cancer

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 7, 2019

Primary Completion Date

March 4, 2021

Study Completion Date

June 5, 2023

Conditions

Urothelial Carcinoma

Interventions

DRUG

RC48-ADC

2.0mg/kg IV every 2 weeks

Trial Locations (8)

100078

Beijing Cancer Hospital, Beijing

Unknown

Anhui Cancer Hospital, Hefei

Cancer Hospital Chinese Academy of Medical Sciences, Beijing

Peking University First Hospital, Beijing

Sun Yat-sen University Cancer Center, Guangzhou

Hunan Cancer Hospital, Changsha

Qilu Hospital of Shandong University, Jinan

West China Hospital, Chengdu

All Listed Sponsors

lead

RemeGen Co., Ltd.

INDUSTRY

NCT03809013 - A Open-label, Single-arm, Multicenter, Phase II Study of RC48-ADC to Evaluate the Efficacy and Safety of Subjects With HER2 Overexpressing Locally Advanced or Metastatic Urothelial Cancer | Biotech Hunter | Biotech Hunter